David Guy Kirsch is an American oncologist currently the Barbara Levine University Professor at Duke University[1] and an Elected Fellow of the American Association for the Advancement of Science.[2]

Education

He earned his M.D. and Ph.D. at Johns Hopkins University School of Medicine in 2000.[3]

Research

His interests are in studying sarcomagenesis, cancer biology and radiation oncology.[2] His highest cited papers are "Conversion of Bcl-2 to a Bax-like death effector by caspases",[4] at 1332 times, and "Restoration of p53 function leads to tumour regression in vivo",[5] at 1320 times, according to Google Scholar.[6]

Publications

References

  1. ^ "Kirsch Lab". duke.edu. Archived from the original on December 10, 2017. Retrieved December 20, 2017.
  2. ^ a b "Three Faculty Elected Fellows AAAS". duke.edu. November 21, 2017. Archived from the original on December 20, 2017. Retrieved December 20, 2017.
  3. ^ "David Kirsch". duke.edu. Archived from the original on February 5, 2018. Retrieved December 20, 2017.
  4. ^ Emily H-Y Cheng, David G Kirsch, Rollie J Clem, Rajani Ravi, Michael B Kastan, Atul Bedi, Kazuyoshi Ueno, J Marie Hardwick. Conversion of Bcl-2 to a Bax-like death effector by caspases. 278:5345. Science. 1997
  5. ^ Andrea Ventura, David G Kirsch, Margaret E McLaughlin, David A Tuveson, Jan Grimm, Laura Lintault, Jamie Newman, Elizabeth E Reczek, Ralph Weissleder, Tyler Jacks. Restoration of p53 function leads to tumour regression in vivo. 445:7128. 661-665. Nature. 2007
  6. ^ "David Kirsch". Archived from the original on February 15, 2023. Retrieved December 20, 2017.